EAM
ITOS

Eagle Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Eagle Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.41M Sell
151,649
-12,583
-8% -$192K 0.01% 474
2024
Q2 		$2.47M Sell
164,232
-69,352
-30% -$994K 0.01% 457
2024
Q1 		$3.12M Buy
+233,584
New +$2.54M 0.02% 436

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eagle Asset Management's ITOS Position: Q3 2024 in Review

Eagle Asset Management reduced its iTeos Therapeutics (ITOS) stake by 7.7% in Q3 2024, selling an estimated $192K and leaving 151,649 shares worth $1.41M. The position accounts for 0.01% of the portfolio, ranked #474.

Eagle Asset Management first reported a position in ITOS in Q1 2024 and has held it in 3 quarters since. The position peaked at $3.12M in Q1 2024. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Eagle Asset Management held 151,649 shares of iTeos Therapeutics worth $1.41M as of Q3 2024.
  • Eagle Asset Management sold 12,583 iTeos Therapeutics shares in Q3 2024, an estimated $192K.
  • iTeos Therapeutics made up 0.01% of Eagle Asset Management's portfolio in Q3 2024, its #474 holding.
  • Eagle Asset Management first reported a position in iTeos Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Eagle Asset Management's iTeos Therapeutics position peaked at $3.12M in Q1 2024.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.